ScreenerHero

NEU Neuren Pharmaceuticals Limited

ASX · AU · Healthcare · Biotechnology · neurenpharma.com
—Mkt Cap: —P/E: —

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults an…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.87BUSDP/E 29.6
MRNA
Moderna, Inc.
$94.42BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$81.99BUSDP/E 19.1
ARGX
argenx SE
$53.47BUSDP/E 32.5
ARGX
argenx SE
$53.22BUSDP/E 31.6
UCB
UCB SA
$44.02BUSDP/E 17.8
ONC
BeOne Medicines AG
$42.56BUSDP/E 66.4
RVMD
Revolution Medicines, Inc.
$40.57BUSD
RPRX
Royalty Pharma plc
$34.45BUSDP/E 30.4
ALNY
Alnylam Pharmaceuticals, Inc.
$31.32BUSDP/E 39.3
ROIV
Roivant Sciences Ltd.
$24.59BUSD
GMAB
Genmab A/S
$23.32BUSDP/E 31.7
GMAB
Genmab A/S
$23.26BUSDP/E 29.8
INCY
Incyte Corporation
$22.96BUSDP/E 14.0
BNTX
BioNTech SE
$22.66BUSD
INSM
Insmed Incorporated
$21.67BUSD
EXEL
Exelixis, Inc.
$15.57BUSDP/E 19.3
ASND
Ascendis Pharma A/S
$14.91BUSDP/E 17.4
JAZZ
Jazz Pharmaceuticals plc
$13.92BUSDP/E 14.7
HALO
Halozyme Therapeutics, Inc.
$13.79BUSDP/E 33.4

Key Statistics

Company
Market Cap—
Enterprise Value1.48B USD
Revenue (TTM)48.05M USD
Gross Profit44.67M USD
Net Income (TTM)21.03M USD
Revenue/Share0.54 AUD
Last Price—
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINNZNEUE0001S8
Valuation
P/E (Trailing)—
P/E (Forward)33.21
PEG—
EV/EBITDA154.54
EV/Revenue30.87
P/S36.14
P/B7.54
EPS (TTM)0.15
EPS (Forward)0.60
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin8.20%
EBITDA Margin19.98%
Profit Margin47.09%
ROE8.99%
ROA8.88%
Growth
Revenue Growth17.30%
Earnings Growth-67.30%
Cash Flow & Leverage
Operating CF3.54M USD
CapEx (TTM)25.57K USD
FCF Margin-19.48%
FCF Yield—
Net Debt-198.02M USD
Net Debt/EBITDA-20.63
Balance Sheet
Debt/Equity—
Current Ratio46.45
Quick Ratio44.56
Book Value/Sh2.63 AUD
Cash/Share2.26 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.15 AUD
Div. Yield1.55%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateSep 15, 2026
Pay Date—
Splits
Last Split1:20
Split DateNov 21, 2017
Analyst Consensus
Rating—
Target (Mean)26.03 AUD
Target Range24.50 AUD – 28.90 AUD
# Analysts6
Ownership
Shares Out.126.77M
Float109.86M
Insiders13.34%
Institutions23.42%
Technical
SMA 5021.00 AUD
SMA 20016.00 AUD
Beta1.57
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)297.65K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—